Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
The academy has secured partnerships with 15 esteemed hospitals
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Ibara will drive AI-powered clinical research innovation
Imfinzi also recommended for patients with mismatch repair deficient disease
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Renews GMP certifications for India and Malaysia sites
Subscribe To Our Newsletter & Stay Updated
